skip to search skip to navigation skip to main content

Archive: Product Launches

Early detection of prostate cancer is key for increasing survival rate in Morocco

27th November 2017 in Product Launches

  Prostate cancer incidence rate in Morocco has increased by 62% from 2004 to 2007[1] 10-20% of patients are diagnosed at a late stage[2], indicating a need for increased awareness around screening and early detection Astellas launches a new prostate cancer treatment that enables physicians to better tailor prostate cancer disease management based on patients’…

Read Full Post

Early detection is key to increase the survival rate of prostate cancer patients

03rd May 2017 in Product Launches

7% of the Egyptian male population are within the age group at risk for prostate cancer[1] Egyptian men who are diagnosed with prostate cancer are 7.2 times more likely to die from the disease as compared with the USA[2] Astellas Pharma launched Xtandi™ – enabling physicians to better tailor prostate cancer disease management according to…

Read Full Post

Patients in Egypt can now benefit from a new first-in-class overactive bladder treatment

24th November 2016 in Product Launches

More than 500 million people around the world are affected by OAB[1] Around 40% of the OAB patients are silent sufferers and have never consulted a physician about their condition[2] Urinary dysfunction should not be considered as natural part of ageing  Astellas Pharma – World category leader in Urology- launches BETMIGA in Egypt  Cairo, Egypt;…

Read Full Post

Astellas Pharma launched its hormonal prostate cancer treatment in three-month dosing

10th November 2016 in Product Launches

More than 11% of the Iranian male population are within the risk age group for prostate cancer [1] Men in the Middle East region are approximately 3 times more likely to die from prostate cancer as compared with the Northern Europe [2] Early detection is more likely to increase the survival rate of prostate cancer…

Read Full Post

Prostate Cancer screening is vitally important for Jordan’s male population over 50

08th November 2016 in Product Launches

More than 8% of the Jordanian male population are within the risk age group for prostate cancer[1] Early detection may increase overall survival rate Currently men in Jordan are 5.3 times more likely to die from prostate cancer as compared with the USA[2] Astellas Pharma launched its prostate cancer treatment Xtandi™ providing effective disease treatment…

Read Full Post

Vesicare Launch in Algeria

16th January 2016 in Product Launches

Algiers, Algeria 10 September 2015. Astellas Middle East, North and Sub-Saharan Africa (MENA/SSA) announced that a new treatment, Solifenacin succinate, has been made available in Algeria for relieving symptoms of overactive bladder (OAB) in adults.1 This includes patients suffering from a strong, sudden urge to urinate without prior warning and having to urinate frequently.1 This…

Read Full Post

Betmiga launched in Jordan

13th January 2016 in Product Launches

Amman, Jordan; January 13, 2016: Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), today announced that a new treatment for relieving symptoms of overactive bladder (OAB) is now available in Jordan. The treatment contains the active ingredient mirabegron, providing a new and alternative treatment option to conventional antimuscarinics treatment for adult patients. OAB is…

Read Full Post

Betmiga launched in Lebanon

13th November 2015 in Product Launches

Beirut, Lebanon; November 13, 2015: Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), today announced that its latest innovative treatment for overactive bladder (OAB) is now available in Lebanon. The oral medication contains the active ingredient mirabegron, and provides a new treatment option for OAB patients. Overactive bladder (OAB) is the name of a…

Read Full Post

Ribomustin launched in Algeria

01st October 2015 in Product Launches

Algiers, Algeria, October 1, 2015: During the 12th annual meeting of the Algerian society of haematology and blood transfusion, Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA) has introduced Bendamustine in Algeria for the treatment of Chronic Lymphocytic Leukaemia (CLL) and Indolent Non-Hodgkin’s Lymphoma (INHL). In 2012 the incidence of Non-Hodgkin’s Lymphoma (NHL) in…

Read Full Post

Vesicare launched in Algeria

10th September 2015 in Product Launches

Algiers, Algeria 10 September 2015. Astellas Middle East, North and Sub-Saharan Africa (MENA/SSA) announced that a new treatment, Solifenacin succinate, has been made available in Algeria for relieving symptoms of overactive bladder (OAB) in adults.1 This includes patients suffering from a strong, sudden urge to urinate without prior warning and having to urinate frequently.1 This…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2018 Astellas Pharma